Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
Scientific Community
Become a Member | Sign in
Home>News>This Article

DefiniGEN Closes £2.3M Series A Fundraising

Published: Monday, June 02, 2014
Last Updated: Monday, June 02, 2014
Bookmark and Share
Funding will be used to launch new stem cell products for drug discovery and regenerative medicine.

DefiniGEN Ltd today announced the final closing of its Series A funding round. The latest £1 million ($1.6 million) placement for ordinary shares brings to a close a cumulative total for the round of £2.28 million ($3.83 million), which will support the international expansion of the business and the commercial launch of new products.

The funding round was led by Cambridge Enterprise and 24 Haymarket, with existing investors Dr. Jonathan Milner, CEO, Abcam Plc, Providence Investment Company, and Cambridge Capital Group also participating. New investors include LBA, Wren Capital, and Ranworth Capital.

This latest funding will be used to drive profitable growth across four key areas:
•         expansion of direct commercial presence across Europe, North America and Asia Pacific with dedicated local marketing presence
•         investment in automation at the Company’s enlarged laboratory facility and recruitment of high quality production staff
•         expansion of product line offerings in new areas including human induced pluripotent stem cell (iPSC) derived hepatocyte types, pancreatic beta cells and lung cells, with others to follow
•         strengthening of the Company’s intellectual property portfolio

DefiniGEN is focused on serving the growing need in the pharmaceutical industry for more accurate predictions of efficacy and toxicity in drug candidates ahead of clinical trials. Its platform technology OptiDIFF is a revolutionary stem cell production platform for the generation of high-functionality cell types including, liver, pancreatic and lung cells. These cells can be used as predictive in vitro models to support the development of safer and more effective treatments for diseases. Since its foundation in April 2012 DefiniGEN has undergone rapid growth, generating first sales within six months of seed investment and securing contracts with global pharma companies.

Commenting on the announcement, Dr Marcus Yeo, CEO of DefiniGEN, said: “We are at an exciting inflexion point in the development of human induced pluripotent stem cell technology. The funds raised will allow the rapid development of libraries of human cells customised for genetic and ethnic profiles for drug discovery and regenerative applications. These advances are generating substantial interest from global pharma.”

Marek Gumienny, Lead Investor, 24 Haymarket, and formerly Chairman of Candover Partners Ltd, said: “DefiniGEN is a dynamic innovative company with a business model that can harness the huge potential of stem cell technology. Stem cells have the power to revolutionise healthcare, radically improve the efficiency and economics of drug development and enable personalised regenerative medicine to become a reality.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

DefiniGEN Licences Lung Stem Cell Technology from University of Cambridge
Technology will be used to develop new, optimized cell products and services for drug discovery.
Tuesday, August 11, 2015
DefiniGEN Announces Closing of £2.3 million ($3.8 million) Series A Fundraising
Funding will be used to launch new stem cell products for drug discovery and regenerative medicine.
Tuesday, June 03, 2014
Scientific News
Genome Engineering Paves Way For Sickle Cell Cure
Researchers from UC Berkeley have used CRISPR-Cas9 gene editing to fix the mutated gene responsible for sickle cell disease.
Preventing Alzheimer's in Mice
Researchers have prevented the Alzheimer’s development in mice by using a virus delivery system to transport a specific gene into the brain.
Link Between Heart and Blood Cells in Early Development Found
Researchers have identifed a key factor in determining the fate of early undifferentiated cells during development.
Scientists Speed Up Muscle Repair
Researchers discovered genetically modified mice were able to support far more regenerative stem cells, for muscle repair, than previously thought.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Nanosensors Could Determine Tumours’ Ability to Remodel Tissue
Researchers design nanosensors that can profile tumours, focusing on protease levels.
Insight into Eye Diseases
Scientists recreate zebrafish cell regeneration from retinal stem cells in mice.
1960s Antibiotics Show Promise for TB Therapy
Research suggests antibiotics introduced in 1963 to treat bacterial infections show promise for tuberculosis therapy.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Studies Explore the Science of Cardiovascular Diseases
Two studies highlight how basic science research insights are key to future treatment breakthroughs.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos